The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous urticaria. However, both drug classes have serious side effects, and many patients still struggle to control their lesions. As a result, the approval of Xolair has been welcomed by physicians and patients. Clinical trials for additional biological therapies are underway, capturing urticaria disease data using an array of clinical scoring systems. With only one biological drug currently approved, the most important factors for driving prescribing decisions remain unknown, and many of the unmet needs in this market remain unfulfilled.

Questions answered

  • What unmet needs remain for chronic urticaria patients after the approval of Xolair?
  • Which clinical trial endpoints and nonclinical attributes are key influencers on dermatologists’ and allergists’ prescribing decisions and which have limited impact? What are potential areas of hidden opportunity?
  • How does Xolair (Novartis / Genentech), approved for chronic idiopathic urticaria in the United States, perform on key treatment drivers and goals? How does its performance compare with that of frequently prescribed conventional therapies, including steroids and antihistamines?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists and allergists for a hypothetical new chronic urticaria drug?

Product description

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 30 European allergists and dermatologists fielded in February 2020

Key companies: Genentech, Novartis

Key drugs: Xolair, ligelizumab, steroids, antihistamines

Table of contents

  • Detailed, Expanded Analysis (US & EU) Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
    • Executive Summary
      • Unmet Need - Chronic Urticaria - Executive Summary - June 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Chronic Urticaria
      • Key Findings: Unmet Need in Chronic Urticaria and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Chronic Urticaria Market and Emerging Therapy Insights
        • Opportunity: A Therapy That Can Induce Remission
        • Opportunity: A Therapy Delivering QOL Improvements
        • Opportunity: A Therapy that Decreases Urticaria Activity
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • [[Indication]] Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulation of a Market Scenario
        • Market Scenario
    • Appendix
      • Experts Interviewed

Author(s): Kristine Mackin, PhD

Kristine Mackin, is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.

Related Reports

Urticaria | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Chronic Inducible Urticaria (US)

MARKET OUTLOOK Chronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU appears to be more resistant than ch...

View Details

Urticaria | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Chronic Spontaneous Urticaria (US)

Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, presents as hives that persist daily or almost daily for six weeks or longer without an obvious known stimulus. Dr...

View Details